Evidence map›Paper›PMID 34115350›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Phage Microarrays for Screening of Humoral Immune Responses.

Ana Montero-Calle, Pablo San Segundo-Acosta, María Garranzo-Asensio, Guillermo Solís-Fernández, Maricruz Sanchez-Martinez, Rodrigo Barderas

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Ana Montero-CalleChronic Disease Programme, UFIEC, Instituto de Salud Carlos III, Madrid, Spain.
Pablo San Segundo-AcostaChronic Disease Programme, UFIEC, Instituto de Salud Carlos III, Madrid, Spain.
María Garranzo-AsensioChronic Disease Programme, UFIEC, Instituto de Salud Carlos III, Madrid, Spain.
Guillermo Solís-FernándezChronic Disease Programme, UFIEC, Instituto de Salud Carlos III, Madrid, Spain.
Maricruz Sanchez-MartinezChronic Disease Programme, UFIEC, Instituto de Salud Carlos III, Madrid, Spain.
Rodrigo BarderasChronic Disease Programme, UFIEC, Instituto de Salud Carlos III, Madrid, Spain. r.barderasm@isciii.es.
Instituto de Salud Carlos III · ESKU Leuven · BEUnidad Funcional de Investigación de Enfermedades Crónicas · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic diseases are the leading cause of disability and responsible for about 63% of deaths worldwide. Among the noninfectious chronic diseases with the highest incidence are cancer and neurodegenerative diseases. Although they have been extensively studied in the last years, there is still an urgent need to find and elucidate the molecular mechanisms underlying their formation and progression to get an early diagnosis and find new therapeutic targets of intervention. Beyond other microarray-based proteomic techniques more extensively used because of their commercial availability, such as protein and antibody microarrays, phage microarrays are another kind of protein microarrays useful for the identification and characterization of disease-specific humoral immune responses and to get further insights into these devastating diseases. Here, we describe the integration and utilization of phage microarrays, which offer such a combination of sensitivity and cost-effective multiplexing capabilities that makes them an affordable strategy for the characterization of humoral immune responses in multiple diseases.

Indexed as

Protein Array AnalysisHumansImmunity, HumoralNeoplasmsNeurodegenerative DiseasesAutoantibodyBiomarkersDiagnostic/prognostic autoantibody biomarkersPhage microarraysProteomics

Identifiers

PMID34115350
OpenAlexW3168212044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.